MAPKAPK2 (MK2) is elevated in fibroblasts and epithelial cells from patients with IPF, and its inhibition has been proposed as a treatment strategy based on pre-clinical models [54]. The gene discussed is MAPKAPK2; the disease is idiopathic pulmonary fibrosis.